This study is not accepting new patients

Expanded Access to Ziftomenib

a study on Acute Lymphoblastic Leukemia Leukemia Acute Myeloid Leukemia Lymphoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Dates
study started
Principal Investigator
by Jerry Lee (ucsf)

Description

Summary

Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL), with appropriate mutations, or Acute Myeloid Leukemia (AML), with NPM1 mutations.

To request access, use Responsible Party contact information provided in this record.

Expanded access for ziftomenib is only available in the United States

Keywords

Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, ziftomenib

Eligibility

For people ages 18 years and up

Inclusion/Exclusion Criteria:

Diagnosed with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Adult, ages 18+

Has exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.

Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.

Meets any other pertinent medical criteria for access to the investigational drug, as established by Kura Oncology

For AML patients: Does not have KMT2A rearrangement

Lead Scientist at University of California Health

  • Jerry Lee (ucsf)
    Assistant Professor, Medicine, School of Medicine. Authored (or co-authored) 20 research publications

Details

Status
not accepting new patients
Start Date
Sponsor
Kura Oncology, Inc.
ID
NCT05738538
Study Type
Expanded Access
Last Updated